Global Generic Drug Litigation Updates 2018: Opportunities for Generic Companies Based on the Latest Para IV Events

  • ID: 4535497
  • Report
  • Region: Global
  • Research Delta Advisors
1 of 4
Provides an Insight into Each Product Opportunity for Generic Companies


  • Actavis
  • Aurobindo
  • Fresenius Kabi
  • MSN Labs
  • Pharma
  • Teva
  • MORE

The report highlights all important opportunities for generic companies based on the latest Para IV litigation updates. The analyses provides an insight into each product opportunity for generic companies in terms of (1) likely timeline of the first generic launch in US (2) potential competition on the first day of launch and (3) companies likely to benefit in case of a probable launch under low competition.

The analyses gets updated every time when an important development as regards the product Para IV litigation happens. In other words, it is not only comprehensive but also updated. This report is published every month covering important updates on Para IV litigations.

Important Para IV events are following events related to Para IV litigations:

  • New Para IV applications filed
  • Litigation dismissals
  • Final judgments
  • Patent related opinions and judgments
  • PTAB updates

Sources of information:

  • US Courts documents
  • Company SEC filings/Annual Reports
  • PTAB
Note: Product cover images may vary from those shown
2 of 4


3 of 4

Companies covered in previous issues include:

  • Actavis
  • Alkem
  • Alvogen
  • Amneal
  • Apotex
  • Aurobindo
  • Bion pharma Lupin
  • Cipla
  • Dr Reddy's
  • Emcure
  • Fresenius Kabi
  • Hetero
  • Jubiliant
  • Lupin
  • Medicare
  • MSN Labs
  • Mylan
  • Natco
  • Par
  • Perrigo
  • Pharma
  • Quilu
  • Sandoz
  • Shilpa
  • SigmaPharma
  • Teva
  • Teva Actavis
  • Torrent
  • Twi
  • Watson
  • Zydus Cadila
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown